Inicio・Lista de Acciones・Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

Cerrado

SectorSanidad

3.48 -4.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.36

Máximo

3.64

Métricas clave
By Trading Economics
Ingresos	171M 123M
BPA	-0.15
Empleados	202
EBITDA	-1.9M -47M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+213.19% upside

Dividendos
By Acuity
Próximas Ganancias	12 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	3.3M 397M
Apertura anterior	7.61
Cierre anterior	3.48

Noticias sobre sentimiento de mercado

By Acuity

47%

53%

123 / 340 Clasificación en Healthcare

Rocket Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 ago 2026, 20:02 UTC

News

Rocket Pharmaceuticals shares are lower after Wedbush cut its price target to $15, reflecting concerns over mixed second-quarter earnings results.

10 ago 2026, 23:26 UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

8 ago 2026, 00:01 UTC

Rocket Pharmaceuticals Inc. shares are higher in after-market trading, advancing modestly since Friday's close and remaining above its 20-day moving average.

7 ago 2026, 23:01 UTC

Rocket Pharmaceuticals Inc. shares have shown little change in after-market trading, remaining within a narrow band since Friday's close.

6 ago 2026, 23:06 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, remaining above its 20-day moving average amid no specific news to explain the movement.

5 ago 2026, 20:02 UTC

News

Rocket Pharmaceuticals is rising Wednesday, driven by a strong Biotechnology sub-sector. The stock remains above its 20-day moving average during the session.

4 ago 2026, 19:26 UTC

News

Event

Rocket Pharmaceuticals shares rise as Wedbush maintains Outperform rating with a $16 price target. The company also reported promising safety results in its Phase 2 trial.

3 ago 2026, 22:01 UTC

Event

Rocket Pharmaceuticals shares are lower in after-market trading despite a positive clinical safety update on its Phase 2 trial for RP-A501.

31 jul 2026, 22:01 UTC

Rocket Pharmaceuticals shares declined in after-hours trading, continuing a downward trend since Friday's close. The stock remains below its 20-day moving average.

30 jul 2026, 21:51 UTC

Rocket Pharmaceuticals is lower in after-market hours, reflecting declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

29 jul 2026, 20:52 UTC

Rocket Pharmaceuticals shares are lower in after-market hours amid a broader market decline driven by rising crude oil prices and geopolitical tensions.

28 jul 2026, 19:22 UTC

Rocket Pharmaceuticals Inc is trading lower today, reflecting broader market trends. The stock remains below its 20-day moving average and near its one-month trading range low.

27 jul 2026, 16:16 UTC

Rocket Pharmaceuticals is trading higher today, recovering from an earlier dip. Broader market volatility follows a notable decline in oil prices amid geopolitical developments.

24 jul 2026, 19:06 UTC

Rocket Pharmaceuticals is trading lower, extending a five-session decline. Broader market pressures and falling crude oil prices are influencing investor sentiment.

22 jul 2026, 20:06 UTC

Rocket Pharmaceuticals shares are lower, marking four consecutive sessions of declines. The stock has closed below its 20-day moving average.

20 jul 2026, 19:46 UTC

News

Rocket Pharmaceuticals shares are higher today amid mixed analyst sentiments, with Wall Street Zen downgrading to "sell" and Chardan Capital maintaining a "buy" rating.

Comparación entre iguales

Cambio de precio

Rocket Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

213.19% repunte

Estimación a 12 Meses

Media 11.4 USD 213.19%

Máximo 15 USD

Mínimo 5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rocket Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Rocket Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

123 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.